The synergistic application of JQ1, a BRD4 inhibitor, mediates the PD-L1 checkpoint blockade, thereby initiating a potent anti-tumor immune response that curbs the recurrence and metastasis of breast cancer tumors [220]. The gene discussed is CD274; the disease is neoplasm.